Sensitive Colorimetric Detection of Interleukin-6
colorimetric detection
interleukin-6
lateral flow immunoassay
paper test strips
point-of-care diagnostics
silver enhancement reagent
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
09
2021
accepted:
04
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
Interleukin-6 (IL-6) is a pro/anti-inflammatory cytokine, the quantitative detection of which has been extensively considered for diagnosis of inflammatory associated diseases. However, there has not yet been a reliable, low-cost, and user-friendly platform developed for point-of-care (POC) detection of IL-6, which will eliminate the conventional costly, time-consuming, and complex assays. In this work, we developed a lateral flow assay for colorimetric detection of IL-6, using anti-IL-6 antibodies conjugated to gold nanoparticles (AuNPs) as the detection probes. Silver amplification technique was incorporated with the newly developed assay in order to enhance the obtained colorimetric signals, allowing sensitive detection of IL-6 in human serum in the desired physiological ranges (i.e., 5-1000 pg/mL). A limit of detection of 5 pg/mL could be achieved for IL-6 detection in serum with the amplification step which was not achievable in the standard assay. The corresponding specificity and reproducibility tests were all preformed to confirm the reliability of this assay for quantitative measurement of IL-6 in a POC manner.
Identifiants
pubmed: 34900966
doi: 10.3389/fbioe.2021.778269
pii: 778269
pmc: PMC8662996
doi:
Types de publication
Journal Article
Langues
eng
Pagination
778269Informations de copyright
Copyright © 2021 Rahbar, Wu, Subramony and Liu.
Déclaration de conflit d'intérêts
Authors YW and JAS were employed by the company AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Bioeng Biotechnol. 2021 Nov 11;9:752514
pubmed: 34858958
Int J Mol Sci. 2019 Nov 28;20(23):
pubmed: 31795299
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Anal Biochem. 2020 Jan 1;588:113468
pubmed: 31585097
Talanta. 2016 May 15;152:521-30
pubmed: 26992550
Nat Rev Cancer. 2008 Nov;8(11):887-99
pubmed: 18846100
Drug Deliv Transl Res. 2020 Aug;10(4):878-902
pubmed: 32367423
Adv Sci (Weinh). 2021 Aug;8(15):e2004433
pubmed: 34114369
Angew Chem Int Ed Engl. 2020 Nov 16;59(47):20754-20766
pubmed: 32521081
ACS Appl Mater Interfaces. 2017 Dec 6;9(48):41659-41668
pubmed: 29119789
Tumour Biol. 2016 Sep;37(9):11553-11572
pubmed: 27260630
Lab Chip. 2019 Jul 23;19(15):2486-2499
pubmed: 31251312
Talanta. 2016;148:272-8
pubmed: 26653449
Biosens Bioelectron. 2019 Jul 1;136:60-75
pubmed: 31035028
Analyst. 2020 Apr 21;145(8):2828-2840
pubmed: 32219225
Anal Bioanal Chem. 2013 Dec;405(30):9859-67
pubmed: 24162821
Bioelectrochemistry. 2020 Aug;134:107532
pubmed: 32305864
J Mater Chem B. 2018 Nov 28;6(44):7102-7111
pubmed: 32254626
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Biosens Bioelectron. 2019 Sep 15;141:111432
pubmed: 31299628
J Nanobiotechnology. 2020 Sep 10;18(1):130
pubmed: 32912236
View (Beijing). 2021 May 04;:20210003
pubmed: 34766163
ACS Sens. 2017 Feb 24;2(2):218-226
pubmed: 28723139
Anal Chim Acta. 2015 Jan 1;853:95-115
pubmed: 25467452
Biosens Bioelectron. 2019 Feb 1;126:806-814
pubmed: 30602262